Oramed Pharmaceuticals (Seite 1654)
eröffnet am 28.03.07 10:26:47 von
neuester Beitrag 07.05.24 21:17:15 von
neuester Beitrag 07.05.24 21:17:15 von
Beiträge: 19.668
ID: 1.121.564
ID: 1.121.564
Aufrufe heute: 21
Gesamt: 1.542.363
Gesamt: 1.542.363
Aktive User: 0
ISIN: US68403P2039 · WKN: A1CTNU · Symbol: OJU1
2,2360
EUR
-3,70 %
-0,0860 EUR
Letzter Kurs 07.05.24 Tradegate
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 0,5700 | +55,23 | |
| 5,4500 | +41,56 | |
| 119,40 | +29,92 | |
| 1,2100 | +21,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 13,800 | -13,86 | |
| 4,1900 | -14,49 | |
| 5,2500 | -19,23 | |
| 0,7500 | -27,88 | |
| 0,7500 | -48,28 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 43.222.640 von occitania am 29.05.12 18:56:48Test 
Test funktioniert
6,25% und das nach der super Kiwi-Meldung
Gruß r
PS. bei mir gibt es heute zum Abendbrot "Eier"
Test funktioniert
6,25% und das nach der super Kiwi-Meldung
Gruß r
PS. bei mir gibt es heute zum Abendbrot "Eier"
Antwort auf Beitrag Nr.: 43.222.519 von occitania am 29.05.12 18:32:41Ganz Einfach,mon ami,Nach die Kangaroo´s sind jetzt die Kiwi dran...
ah ja, das leuchtet mir ein
als nächstes kommen dann die Krokodile dran
Gruß r
ah ja, das leuchtet mir ein
als nächstes kommen dann die Krokodile dran
Gruß r
Antwort auf Beitrag Nr.: 43.222.470 von reaaalist am 29.05.12 18:26:09Salut reaaalist
Ich bitte um eine kurze Stellungnahme
Ganz Einfach,mon ami,Nach die Kangaroo´s sind jetzt die Kiwi dran...
à bientôt
OC
Post scriptum:Bin gerade nach Hause gekommen...brauche 1bisschen Zeit
Ich bitte um eine kurze Stellungnahme
Ganz Einfach,mon ami,Nach die Kangaroo´s sind jetzt die Kiwi dran...
à bientôt
OC
Post scriptum:Bin gerade nach Hause gekommen...brauche 1bisschen Zeit
Antwort auf Beitrag Nr.: 43.222.076 von reaaalist am 29.05.12 17:20:25Salut reaaalist
Ja....Ja....
das "Zäpfchen" geht langsam ab....
Ich gratuliere....sieht so aus ob du 1 Paare guter News bei Oramed giessen kann....
10 Eier.....
à bientôt
OC
Ja....Ja....
das "Zäpfchen" geht langsam ab....
Ich gratuliere....sieht so aus ob du 1 Paare guter News bei Oramed giessen kann....
10 Eier.....
à bientôt
OC
Trading Spotlight
Antwort auf Beitrag Nr.: 43.222.076 von reaaalist am 29.05.12 17:20:25Moin Occi,
New Zealand
wieso da, verstehe ich nicht!
Du?
Ich bitte um eine kurze Stellungnahme
Gruß r
New Zealand
wieso da, verstehe ich nicht!
Du?
Ich bitte um eine kurze Stellungnahme
Gruß r
Moin Oramedisten
das "Zäpfchen" geht langsam ab.....
Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
JERUSALEM, May 29, 2012- Oramed Pharmaceuticals Inc. (OTCBB:ORMP.OB) (www.oramed.com), a developer of oral drug delivery systems, announced today that it has received approval for a key patent by the New Zealand Patent Office. The patent, entitled "Methods and Compositions for Oral Administration of Exenatide," covers oral exenatide compositions made using the company's technology. Oramed's portfolio now consists of three issued patents and 34 patents pending for its technologies and products.
Exenatide is a GLP-1 analogue, and is a highly effective medication for the management of Type 2 diabetes (T2DM). The physiological pathways it engages to lower blood glucose levels generate a sparing impact on the pancreatic beta cells, blunting their gradual exhaustion - a typical marker of late-stage T2DM. In addition to the drug's intrinsic benefits, results with Oramed's oral exenatide formula did not induce nausea among volunteers - a debilitating side effect of exenatide injections - presenting an advantage that could have a considerable impact on the use of this drug. Trials evaluating the safety and efficacy Oramed's GLP-1 analog formulation in diabetic patients are planned to commence in Q3 2012.
Nadav Kidron, CEO of Oramed, commented: "We are very pleased with this news regarding our third patent approval and the inclusion of New Zealand in our global patent network. This particular patent - the first on our oral exenatide formulation - allows Oramed to gain yet more ground in the biotechnology world. We look forward to more patents being approved in the future."
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials, and with its GLP-1 analog capsule, currently entering Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.
For more information, the content of which is not part of this press release,
please visit www.oramed.com
Safe Harbor for Forward-Looking Statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our expectations for additional patents, our technologies and their validation and the possibility of increased patient compliance resulting from our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.
Company and Investor Relations Contact:
Oramed Pharmaceuticals
Aviva Sherman
USA: +1 646-240-4193
Int'l: + 972-54-792-4438
Email: aviva@oramed.com
www.oramed.com
Gruß r
das "Zäpfchen" geht langsam ab.....
Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
JERUSALEM, May 29, 2012- Oramed Pharmaceuticals Inc. (OTCBB:ORMP.OB) (www.oramed.com), a developer of oral drug delivery systems, announced today that it has received approval for a key patent by the New Zealand Patent Office. The patent, entitled "Methods and Compositions for Oral Administration of Exenatide," covers oral exenatide compositions made using the company's technology. Oramed's portfolio now consists of three issued patents and 34 patents pending for its technologies and products.
Exenatide is a GLP-1 analogue, and is a highly effective medication for the management of Type 2 diabetes (T2DM). The physiological pathways it engages to lower blood glucose levels generate a sparing impact on the pancreatic beta cells, blunting their gradual exhaustion - a typical marker of late-stage T2DM. In addition to the drug's intrinsic benefits, results with Oramed's oral exenatide formula did not induce nausea among volunteers - a debilitating side effect of exenatide injections - presenting an advantage that could have a considerable impact on the use of this drug. Trials evaluating the safety and efficacy Oramed's GLP-1 analog formulation in diabetic patients are planned to commence in Q3 2012.
Nadav Kidron, CEO of Oramed, commented: "We are very pleased with this news regarding our third patent approval and the inclusion of New Zealand in our global patent network. This particular patent - the first on our oral exenatide formulation - allows Oramed to gain yet more ground in the biotechnology world. We look forward to more patents being approved in the future."
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials, and with its GLP-1 analog capsule, currently entering Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.
For more information, the content of which is not part of this press release,
please visit www.oramed.com
Safe Harbor for Forward-Looking Statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our expectations for additional patents, our technologies and their validation and the possibility of increased patient compliance resulting from our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.
Company and Investor Relations Contact:
Oramed Pharmaceuticals
Aviva Sherman
USA: +1 646-240-4193
Int'l: + 972-54-792-4438
Email: aviva@oramed.com
www.oramed.com
Gruß r
Antwort auf Beitrag Nr.: 43.213.284 von occitania am 25.05.12 21:58:44Wanduhr wünscht euch allen ein schönes Pfingstfest und hat da etwas gefunden........
http://www.youtube.com/watch?v=TiH5BsVTcyg
Viel Spaß und bleibt gesund
Nur Spaß
http://www.youtube.com/watch?v=TiH5BsVTcyg
Viel Spaß und bleibt gesund
Nur Spaß
Antwort auf Beitrag Nr.: 43.213.284 von occitania am 25.05.12 21:58:44Hey Occi,
wir müssen die Party verschieben!
Heute nichts los mit unserer Perle.
Es fing vielversprechend an.....und hörte auf
Ich wünsche Dir und allen Oramedisten ein schönes Pfingstfest.
Sorry, aber der Rotwein heute macht mich sehr müde, ich muß wohl mal die Sorte wechseln
Gruß r
wir müssen die Party verschieben!
Heute nichts los mit unserer Perle.
Es fing vielversprechend an.....und hörte
auf Ich wünsche Dir und allen Oramedisten ein schönes Pfingstfest.
Sorry, aber der Rotwein heute macht mich sehr müde, ich muß wohl mal die Sorte wechseln
Gruß r
Durchsuchen
Oramed Pharmaceuticals
